MedTrace Logo

Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome

NCT04518319 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-04-18

No results posted yet for this study

Summary

This is a single-center, randomized, parallel-control study conducted in schizophrenic inpatients with metabolic syndrome who have been conducted with olanzapine. The purpose of this study is to evaluate the efficacy and safety of omega-3 polyunsaturated fatty acids, Xbox aerobic exercise and transcranial direct current stimulation( tDCS). Following a screening period, subjects who meet the entry criteria will be randomized to treated with omega-3 polyunsaturated fatty acids1.2mg per day, Xbox aerobic exercise 30min per day and tDCS at 2mA, 20 min(5 session/week) for 12 weeks.

Conditions

Interventions

DRUG

Omega-3 polyunsaturated fatty acids

Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.

BEHAVIORAL

Xbox aerobic exercise

Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.

DEVICE

transcranial direct current stimulation,tDCS

Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.

DRUG

Olanzapine

Patients will take only olanzapine pills.

Sponsors & Collaborators

  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • Yan Chen · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04518319 on ClinicalTrials.gov